January 8, 2021 -- CureVac and Bayer have signed a collaboration and services agreement to develop a new class of medicines based on messenger RNA (mRNA), starting with CureVac's COVID-19 vaccine candidate, CVnCoV.
Bayer will contribute its expertise and infrastructure toward clinical operations, regulatory affairs, pharmacovigilance, medical information, and supply chain performance in selected countries.
CureVac will be the marketing authorization holder while Bayer will support CureVac with country operations within the European Union and selected additional markets. Bayer holds further options to become the marketing authorization holder in markets outside of Europe.
No financial terms of the agreement were disclosed.
Copyright © 2021 scienceboard.net